U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known		
				Application Number	10/722,000-Conf. #6530
INF	ORMATIO	N DIS	CLOSURE	Filing Date	November 25, 2003
ST	STATEMENT BY APPLICANT			First Named Inventor	Brian R. MURPHY
				Art Unit	1648
	(Use as many sheets as necessary)			Examiner Name	Z. Lucas
Sheet 1 of 4		Attorney Docket Number	1173-1049PUS5		

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA*	US-5,716,821-A	02-20-1998	WERTZ, et al.	
000000000000000000000000000000000000000	••• ••••••••••••••	U& 6,780,220	-08-04-4008	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
	AC*	US-5,869,036	02-09-1999	BELSHE, et al.	
	AD*	US-6,264,957-B1	07-24-2001	COLLINS	
•					

	FOREIGN PATENT DOCUMENTS								
Initials* N	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,				
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear				
	ВА	WO-93/21310	10-28-1993						
	ВВ	WO-97/06270	02-20-1997						
	вс	WO-97/12032	04-03-1997						
	BD	WO-97/20468	06-12-1997						
	BE	EP-0 440 219-A1	08-07-1991						
	BF	EP-0 702 085-A1	03-20-1996						
	BG	WO-98/02530	01-22-1998						
	вн	WO-98/43668	10-08-1998						
	ВІ	WO-99/15631	04-01-1999						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *CEX-MINEC: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449/PTO				Complete if Known
				Application Number	10/722,000-Conf . #6530
	NFORMATION	I DI	SCLOSURE	Filing Date	November 25, 2003
S	STATEMENT BY APPLICANT			First Named Inventor	Brian R. MURPHY
				Art Unit	1648
	(Use as many sheets as necessary)			Examiner Name	Z. Lucas
Sheet	sheet 2 of 4		Attorney Docket Number	1173-1049PUS5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Baron et al., "Rescue of Rinderpest Virus from Cloned cDNA," J. Virol. 71:1265-1271, 1997	
	СВ	Buchholz et al., "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter," J. Virol. 73:251-259, 1999	
	СС	Bukreyev, et al., "Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene," J. Virol. 70:6634-41, 1996	
	CD	Bukreyev, et al., "Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity," Proc. Nat. Acad. Sci. USA 96:2367-2372, 1999	
	CE	Collins et al., "Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene," Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991	
	CF	Collins et al., "Rescue of a 7502-Nucleotide (49.3% of Full Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA," Virology 195:252-256, 1993	
	200000000000000	Collins, et al., "Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role of the Transcription Florgation Factor from the 5' Proximal Open	0000000
	CG	Reading Frame of the M2 MRNA in Gene Expression and Provides a Capability for Vaccine Development," Proc. Nat. Acad. Sci. USA 92:11563-11567, 1995	
	СН	Connors et al., "A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes," Virology 208:478-484, 1995	
	CI	Conzelmann et al., "Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid- Encoded Proteins," J. Virol, 68:713-719, 1994	
	Cl	Conzelmann, "Genetic Manipulation of Non-Segmented Negative-strand RNA Viruses," J. Gen. Virol. 77:381-389, 1996	
	СК	Crowe, et al., "A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type challenge in Seronegative Chimpanzees," Vaccine 12:893-790, 1994	
	CL	Crowe, et al., "Acquisition of the <i>ts</i> Phenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene," Virus Genes 13:269-273, 1996	
	СМ	Dimock, et al., "Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3," J. Virol, 67:2772-2778, 1993	
	CN	Durbin, et al., "Minimum Protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus type 3 and Evaluation of the Rule of Six," Virology 234:74-83, 1997	
	со	Durbin et al., "Recovery of Infectious Human Parainfluenza virus type 3 from cDNA," Virology 235:323-332, 1997	

Examiner	I Data	
Exammel	Date	
Cimmatuma	Compiler and	
Signature	t Considered	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known		
				Application Number	10/722,000-Conf . #6530
	NFORMATIO	N DIS	SCLOSURE	Filing Date	November 25, 2003
8	STATEMENT	BY A	PPLICANT	First Named Inventor	Brian R. MURPHY
				Art Unit	1648
	(Use as many sheets as necessary)			Examiner Name	Z. Lucas
Sheet	Sheet 3 of 4		Attorney Docket Number	1173-1049PUS5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
000000000000000000000000000000000000000		Firestone et al., "Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A	
	01	Candidate," Virology 225:419-422, 1996	
	cq	Grosfeld et al., "RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Required RSV Superinfection for Efficient Synthesis of Full-Length MRNA," J. Viorol. 69: 5677-5686, 1995	
	CR	He et al., "Recovery of Infectious SV5 from Cloned DNA and Expression of a foreign Gene," Virology 237:249-260, 1997	
	cs	Hoffman et al., "An Infectious Clone of Human Parainfluenza virus Type 3, "J. Virol. 71:4272-4277, 1997	
	СТ	Jin et al., "Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV," Virology 251:206-214, 1998	
	CU	Juhasz et al., "The Temperature-Sensitive (ts) Phenotype of a Cold-Passaged (cp) Live Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designated cpts530, Results from a Single Amino Acid Substitution in the L Protein," J. Virol. 71:5814-5819, 1997	
	CV	Kato et al., "Initiation of Sendai Virus Multiplication From Transfected cDNA or RNA with Negative or Positive Sense," Genes to Cells 1:569-579, 1996	
	CW	Kuo et al., "Effect of Mutations in the Gene-Start and Gene-End Sequence Motifs on Transcription of Monocistronic and Dicistronic Minigenomes of Respiratory Syncytial Virus," J. Virol. 70:6892-6901, 1996	
	СХ	Lawson et al., "Recombinant Vesicular Stomatitis Viruses from DNA," Proc. Natl. Acad. Sci. USA 92:4477-4481, 1995	
	CY	McIntosh et al., "Respiratory syncytial Virus," in virology, pp. 1046 and 1047, Fields et al., eds., 2nd ed., Raven Press, Ltd, New York, 1990	
	CZ	Mink, et al., "Nucleotide Sequences of the e' Leader and 5' Trailer Regions of Human Respiratory Syncytial Virus Genomic RNA," Virology 185:615-624, 1991	
	CA1	Murphy et al., "Current Approaches to the Development of Vaccines Effective Against Parainfluenza and Respiratory Syncytial Viruses," Virus Res. 11:1-15, 1988	
	CB1	Palese et al., "Negative-Strand RNA Viruses: Genetic Engineering and Applications," Proc. Natl. Acad. Sci. USA 93:11354-11358, 1996	
	CC1	Pastey et al., "Structure and Sequence Comparison of Bovine Respiratory Syncytial Virus Fusion Protein," Virus. Res. 29:195-202, 1993	
	CD1	Pastey et al., "Nucleotide Sequence Analysis of the Non-Structural NS1(1C) and NS2 (1B) Protein Genes of Bovine Respiratory Syncytial Virus." J. of Gen. Virol. 76:193-197, 1995	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known			
				Application Number	10/722,000-Conf. #6530
	NFORMATIC	ON DIS	CLOSURE	Filing Date	November 25, 2003
8	STATEMENT	BY A	PPLICANT	First Named Inventor	Brian R. MURPHY
				Art Unit	1648
	(Use as many sheets as necessary)			Examiner Name	Z. Lucas
Sheet	heet 4 of 4		Attorney Docket Number	1173-1049PUS5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CE1	Peeters et al., "Rescue of Newcastle Disease Virus from Cloned cDNA: Evidence that Cleavability of the Fusion Protein is a Major Determinant for Virulence," J. Virol. 73:5001-5009, 1999	
	CF1	Radecke et al., "Rescue of Measles Viruses from Cloned DNA," EMBO J. 14:5773-5784, 1995	
	CG1	Roberts et al., "Recovery of Negative-Strand RNA Viruses from Plasmid DNAs: A Positive Approach Revitalizes a Negative Field," Virology 247-1-6, 1998	
	CH1	Sakai et al., "Accommodation of Foreign Genes Into The Sendai Virus Genome: Sizes of Inserted Genes and Viral Replication," FEBS Letters 456:221-226, 1999	
	CI1	Schneider et al., "Recombinant Measles Viruses defective for RNA Editing and V. Protein Synthesis Are Viable in Cultured Cells," Virology 277:314-322, 1997	
	CJ1	Schnell et al., "Infectious Rabies Viruses from Cloned cDNA," EMBO J. 13:4195-4203, 1994	
	CK1	Skiadopoulos et al., "Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (<i>cp</i> 45) Human Parainfluenza Virus 3 Candidate Vaccine," J. Virol, 73:1374-1381, 1999	
	CL1	Tao et al., "Recovery of a Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3 in Which the Hemagglutinin-Neuraminidase and Fusion Glycoproteins Have Been Replaced by Those of PIV Type 1," J. Virol. 72:2955-2961, 1998	
	CM1	Tao et al., "A Live Attenuated Recombinant Chimeric Parainfluenza Virus (PIV) Candidate Vaccine Containing the Hemagglutinin-Neuraminidase and Fusion Glycoproteins of PIV1 and the Remaining Proteins from PIV3 Induces Resistance to PIV1 Even in Animals Immune to PIV3" Vaccine 17:1101-1108, 1999	
	CN1	Wathen et al., "Characterization of a Novel Human Respiratory Syncytial Virus Chimeric FG Glycoprotein Expressed Using a Baculovirus Vector," J. Gen Virol. 70:2625-2635, 1989	
	CO1	Whelan et al., "Efficient Recovery of Infectious Vesicular Stomatitis Virus Entirely From cDNA Clones," Proc. Natl. Acad. Sci. USA 92:8388-7392,1995	
	CP1	Whitehead et al., "A Single Nucleotide Substitution inn the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate <i>cpts</i> 243/404 is the Major Determinant of the Temperature-Sensitive and Attenuation Phenotypes," Virology 247:232-239, 1998a	
	CQ1	Whitehead et al., "Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from cold-Passaged RSV is Attenuated in Chimpanzees," J. Virol. 72:4467-4471, 1998b	
	CR1	Whitehead et al., "Recombinant Respiratory Syncytial Virus Bearing a Deletion of Either the NS2 or SH Gene is Attenuated in Chimpanzees," J. Virol. 73:3438-3442, 1999	

Examiner	/Zachariah Lucas/	Date	01/27/2009
Signature		Considered	01/21/2005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is atlached.